Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Table 3 Summary of the subgroup analysis for the primary outcomes

Category	Outcomes	Subgroups	No. of studies	Pooled effect estimate [95% CI]	Subgroup difference (P-value, I^2)
Presence of previous failures	MMD 3 months	No failure	3	-1.24 [-1.82: -0.67]	P = 0.02*, I^2 = 80.3%
	MMD 3 months	Prior failure	5	-2.58 [-3.60: -1.57]	P = 0.02*, I^2 = 80.3%
	MSMD 3 months	No failure	3	-0.92 [-1.25: -0.59]	P = 0.010*, I^2 = 85.1%
	MSMD 3 months	Prior failure	4	-1.93 [-2.62: -1.24]	P = 0.010*, I^2 = 85.1%
	≥ 50% reduction in MMD	No failure	3	1.38 [1.16: 1.65]	P = 0.0007*, I^2 = 91.4%
	≥ 50% reduction in MMD	Prior failure	4	2.28 [1.82: 2.85]	P = 0.0007*, I^2 = 91.4%
Type of migraine	MMD 3 months	Episodic	6	-1.80 [-2.53: -1.06]	P = 0.53, I^2 = 0%
	MMD 3 months	Chronic	2	-2.14 [-2.93: -1.35]	P = 0.53, I^2 = 0%
	≥ 50% reduction in MMD	Episodic	5	1.57 [1.27: 1.93]	P = 0.74, I^2 = 0%
	≥ 50% reduction in MMD	Chronic	2	1.47 [1.10: 1.98]	P = 0.74, I^2 = 0%
Dose of Erenumab	MMD 3 months	70 mg	7	-1.39 [-1.77: -1.01]	P = 0.07, I^2 = 69.8%
	MMD 3 months	140 mg	5	-2.36 [-3.34: -1.38]	P = 0.07, I^2 = 69.8%
	MSMD 3 months	70 mg	6	-1.18 [-1.69: -0.67]	P = 0.01*, I^2 = 84%
	MSMD 3 months	140 mg	4	-1.99 [-2.35: -1.62]	P = 0.01*, I^2 = 84%
	≥ 50% reduction in MMD	70 mg	8	1.47 [1.28: 1.68]	P = 0.15, I^2 = 52.7%
	≥ 50% reduction in MMD	140 mg	5	1.57 [1.40: 1.76]	P = 0.15, I^2 = 52.7%

ISSN: 1746-160X